Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

Condition:   Triple Negative Breast Cancer (TNBC) Interventions:   Drug: Camrelizumab;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel Sponsor:   Aiping Shi Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials